Tumor immunosuppressive environment: Effects on tumor-specific and nontumor antigen immune responses

Expert Review of Anticancer Therapy

Volumn 9, Issue 9, 2009, Pages 1317-1332

  De Souza, Ana Paula ^a   Bonorino, Cristina ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Immunosuppression; Tumor; Tumor nonspecific immunosuppression; Tumor specific immunosuppression

Indexed keywords

COLONY STIMULATING FACTOR 1; GANGLIOSIDE; INTERLEUKIN 10; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MICROENVIRONMENT; NONHUMAN; PROTEIN FUNCTION; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASM STAGING; NEOPLASMS; QUALITY OF LIFE;

EID: 70350647412     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.88     Document Type: Review

References (235)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
2. Rygaard J, Povlsen CO. The mouse mutant nude does not develop spontaneous tumors: an argument against immunological surveillance. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 82(1), 99-106 (1974).
3. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183(124), 534-536 (1974).
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002). •• Excellent review that unveils the concept of immunoediting and discusses key studies that support immunosurveillance and immunoediting. (Pubitemid 35363648)
5. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16), 3491-3494 (1998).
6. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2(4), 293-299 (2001).
7. Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003). • Discusses whether recognition of tumor antigens by the immune system leads to activation or tolerance, and analyzes existing evidence that while immune surveillance systems operate at early stages of tumorigenesis, established tumors primarily induce immune tolerance. (Pubitemid 37174548)
8. Shankaran V, Ikeda H, Bruce AT et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107-1111 (2001). (Pubitemid 32391043)
9. + T cell anergy and promotes tumor rejection. J. Immunol. 177(7), 4521-4529 (2006).
10. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6(11), 836-848 (2006).
11. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 19(2), 203-208 (2007).
12. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 27(45), 5894-5903 (2008).
13. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005). •• Asks why tumor immunotherapy results in a generally poor clinical efficiency, suggesting that the reason might lie in the increasingly documented fact that tumours develop diverse strategies that evade tumor-specific immunity. (Pubitemid 40488632)
14. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat. Rev. Immunol. 6(9), 659-670 (2006). (Pubitemid 44298215)
15. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996). •• First paper to demonstrate the role of VEGF in dendritic cell suppression. VEGF is today a largely studied molecule since it regulates tumor growth though a series of different mechanisms.
16. Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic anti-tumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther. 9(1), 109-115 (2002). (Pubitemid 34052860)
17. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol. Rev. 182, 68-79 (2001).
18. Conrad CT, Ernst NR, Dummer W, Brocker EB, Becker JC. Differential expression of transforming growth factor β 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J. Exp. Clin. Cancer Res. 18(2), 225-232 (1999). (Pubitemid 29359409)
19. Rodeck U, Bossler A, Graeven U et al. Transforming growth factor β production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54(2), 575-581 (1994). (Pubitemid 24053203)
20. +) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92(12), 4778-4791 (1998).
21. Duluc D, Delneste Y, Tan F et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110(13), 4319-4330 (2007).
22. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. 163(7), 3718-3726 (1999). (Pubitemid 29450894)
23. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61(1), 363-369 (2001). (Pubitemid 32095739)
24. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170(7), 3488-3494 (2003). (Pubitemid 36359214)
25. Bennaceur K, Popa I, Chapman JA et al. Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells. Glycobiology 19(6), 576-582 (2009).
26. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998).
27. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000).
28. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004). (Pubitemid 39620069)
29. Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160(3), 1224-1232 (1998). (Pubitemid 28093419)
30. Kryczek I, Lange A, Mottram P et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65(2), 465-472 (2005).
31. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
32. Gholamin M, Moaven O, Memar B et al. Overexpression and interactions of interleukin-10, transforming growth factor β, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J. Surg. 33(7), 1439-1445 (2009).
33. Hu J, Xu Y, Shen ZZ et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in a-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J. Cancer Res. Clin. Oncol. DOI: 10.1007/s00432-009-0663-8 (2009) (Epub ahead of print).
34. Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S. Prognostic significance of angiogenic/lymphangiogenic, antiapoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk. Res. 50(3), 366-373 (2009).
35. Segawa Y, Oda Y, Yamamoto H et al. Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. Oncol. Rep. 21(5), 1197-1202 (2009).
36. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193(2), F5-F9 (2001). (Pubitemid 32524446)
37. Mullins DW, Martins RS, Burger CJ, Elgert KD. Tumor cell-derived TGF-β and IL-10 dysregulate paclitaxel-induced macrophage activation. J. Leukoc. Biol. 69(1), 129-137 (2001).
38. Zou W, Machelon V, Coulomb-L'Hermin A et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7(12), 1339-1346 (2001). (Pubitemid 33785523)
39. Rich JN. The role of transforming growth factor-β in primary brain tumors. Front. Biosci. 8, E245-E260 (2003).
40. Augoff K, Grabowski K, Rabczynski J, Kolondra A, Tabola R, Sikorski AF. Expression of decorin in esophageal cancer in relation to the expression of three isoforms of transforming growth factor-β (TGF-β1, -β2, and -β3) and matrix metalloproteinase-2 activity. Cancer Invest. 27(4), 443-452 (2009).
41. Xiong B, Yuan HY, Hu MB et al. Transforming growth factor-β1 in invasion and metastasis in colorectal cancer. World J. Gastroenterol. 8(4), 674-678 (2002). (Pubitemid 34918662)
42. Chod J, Zavadova E, Halaska MJ, Strnad P, Fucikova T, Rob L. Preoperative transforming growth factor-β 1 (TGF-β 1) plasma levels in operable breast cancer patients. Eur. J. Gynaecol. Oncol. 29(6), 613-616 (2008).
43. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
44. Wahl SM, Wen J, Moutsopoulos N. TGF-β: a mobile purveyor of immune privilege. Immunol. Rev. 213, 213-227 (2006). (Pubitemid 44401503)
45. + T cells in patients with melanoma. J. Immunol. 175(9), 6169-6176 (2005).
46. Geissmann F, Revy P, Regnault A et al. TGF-β 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162(8), 4567-4575 (1999). (Pubitemid 29314856)
47. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 1(5), 412-420 (2008).
48. Alcocer-Gonzalez JM, Berumen J, Tamez-Guerra R et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 19(3), 481-491 (2006). (Pubitemid 44735060)
49. Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM, Burguete A, Madrid-Marina V. Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest. 26(10), 1037-1043 (2008).
50. Hernandez AM, Toledo D, Martinez D et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J. Immunol. 181(9), 6625-6634 (2008).
51. Aarnoudse CA, Garcia Vallejo JJ, Saeland E, van Kooyk Y. Recognition of tumor glycans by antigen-presenting cells. Curr. Opin. Immunol. 18(1), 105-111 (2006). (Pubitemid 43049656)
52. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249-293 (2004).
53. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61(11), 4375-4381 (2001). (Pubitemid 32685762)
54. Joki T, Heese O, Nikas DC et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 60(17), 4926-4931 (2000). (Pubitemid 30701510)
55. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161(6), 2804-2809 (1998).
56. + T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173(7), 4352-4359 (2004).
57. Herfs M, Herman L, Hubert P et al. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol. Immunother. 58(4), 603-614 (2009).
58. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1), 230-237 (2002). (Pubitemid 35177452)
59. Singh B, Cook KR, Vincent L et al. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J. Surg. Res. 147(2), 240-246 (2008).
60. Pandey M, Prakash O, Santhi WS, Soumithran CS, Pillai RM. Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation. Int. J. Oral Maxillofac. Surg. 37(4), 379-383 (2008).
61. Karahan N, Guney M, Baspinar S, Oral B, Kapucuoglu N, Mungan T. Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 28(3), 184-188 (2007). (Pubitemid 46985638)
62. Steffensen KD, Waldstrom M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int. J. Gynecol. Cancer 17(4), 798-807 (2007). (Pubitemid 47063320)
63. Wagemakers M, van der Wal GE, Cuberes R et al. COX-2 inhibition combined with radiation reduces orthotopic glioma outgrowth by targeting the tumor vasculature. Transl. Oncol. 2(1), 1-7 (2009).
64. Seno H, Oshima M, Ishikawa TO et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(δ716) mouse intestinal polyps. Cancer Res. 62(2), 506-511 (2002). (Pubitemid 34110434)
65. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58(2), 362-366 (1998). (Pubitemid 28047080)
66. Coussens LM, Werb Z. Inflammation and cancer. Nature 420(6917), 860-867 (2002).
67. Sombroek CC, Stam AG, Masterson AJ et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168(9), 4333-4343 (2002).
68. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 23(3), 144-150 (2002).
69. Menetrier-Caux C, Thomachot MC, Alberti L, Montmain G, Blay JY. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 61(7), 3096-3104 (2001). (Pubitemid 32691960)
70. Park SJ, Nakagawa T, Kitamura H et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173(6), 3844-3854 (2004). (Pubitemid 39280747)
71. Kryczek I, Grybos M, Karabon L, Klimczak A, Lange A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity. Br. J. Cancer 82(3), 621-628 (2000). (Pubitemid 30085200)
72. + T cell-mediated suppression by dendritic cells. Science 299(5609), 1033-1036 (2003).
73. Yang XO, Pappu BP, Nurieva R et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR α and ROR γ. Immunity 28(1), 29-39 (2008).
74. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 453(7198), 1051-1057 (2008). (Pubitemid 351871737)
75. Grivennikov S, Karin E, Terzic J et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2), 103-113 (2009).
76. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol. 66(1), 27-30 (1997). (Pubitemid 27329303)
77. Melichar B, Savary C, Kudelka AP et al. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin. Cancer Res. 4(3), 799-809 (1998). (Pubitemid 28193581)
78. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002). (Pubitemid 34887242)
79. Munn DH, Sharma MD, Lee JR et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297(5588), 1867-1870 (2002).
80. +) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol. 167(10), 5583-5593 (2001).
81. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165(2), 779-785 (2000).
82. Mazzoni A, Bronte V, Visintin A et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168(2), 689-695 (2002). (Pubitemid 34049569)
83. Baleeiro RB, Barbuto JA. Local secretion/shedding of tumor-derived CD83 molecules as a novel tumor escape mechanism. Mol. Immunol. 45(12), 3502-3504 (2008).
84. Baleeiro RB, Bergami-Santos PC, Tomiyoshi MY et al. Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it? Cancer Immunol. Immunother. 57(2), 265-270 (2008).
85. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61(12), 4756-4760 (2001). (Pubitemid 32691887)
86. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166(1), 678-689 (2001). (Pubitemid 32038493)
87. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55(3), 237-245 (2006). (Pubitemid 41683212)
88. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv. Exp. Med. Biol. 601, 213-223 (2007).
89. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64(17), 6337-6343 (2004). (Pubitemid 39129439)
90. Rodriguez PC, Hernandez CP, Quiceno D et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202(7), 931-939 (2005). (Pubitemid 41396893)
91. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13(2Pt 2), 721s-726s (2007). (Pubitemid 46220098)
92. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67(9), 4507-4513 (2007). (Pubitemid 46815102)
93. Zea AH, Rodriguez PC, Atkins MB et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65(8), 3044-3048 (2005).
94. Fricke I, Mirza N, Dupont J et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13(16), 4840-4848 (2007). (Pubitemid 47298146)
95. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24(6), 431-446 (2001). (Pubitemid 33104863)
96. Rodriguez PC, Zea AH, DeSalvo J et al. l-arginine consumption by macrophages modulates the expression of CD3 ζ chain in T lymphocytes. J. Immunol. 171(3), 1232-1239 (2003). (Pubitemid 36900052)
97. Terabe M, Matsui S, Park JM et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198(11), 1741-1752 (2003). (Pubitemid 37494166)
98. low regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 182(10), 6207-6216 (2009).
99. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5(8), 641-654 (2005). (Pubitemid 41113195)
100. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194(6), 769-779 (2001). (Pubitemid 32983013)
101. +) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192(9), 1213-1222 (2000).
102. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193(2), 233-238 (2001). (Pubitemid 32524454)
103. + regulatory T cell proliferation. J. Exp. Med. 202(7), 919-929 (2005). • Elegantly demonstrates link between tumor growth, recruitment of dendritic cells and Treg cells.
104. + T cells in the periphery. Nat. Rev. Immunol. 7(3), 231-237 (2007).
105. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
106. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004). (Pubitemid 39273735)
107. Weiner HL. Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol. Rev. 182, 207-214 (2001).
108. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13(3), 108-116 (2007). (Pubitemid 46341958)
109. + regulatory T cells in tumor bearing host. Cell Mol. Immunol. 6(1), 3-13 (2009).
110. - T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β 1. J. Immunol. 182(1), 111-120 (2009).
111. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200(6), 771-782 (2004).
112. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32(11), 3267-3275 (2002).
113. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16(2), 157-162 (2004).
114. Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168(9), 4272-4276 (2002). (Pubitemid 34441324)
115. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169(5), 2756-2761 (2002).
116. + T-cells in chronic lymphocytic leukemia. Leuk. Lymphoma 50(5), 788-801 (2009).
117. Nicholaou T, Ebert LM, Davis ID et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin. Cancer Res. 15(6), 2166-2173 (2009).
118. +) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61(12), 4766-4772 (2001).
119. Adurthi S, Krishna S, Mukherjee G, Bafna UD, Devi U, Jayshree RS. Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. Am. J. Reprod. Immunol. 60(1), 55-65 (2008). (Pubitemid 351844100)
120. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98(5), 1089-1099 (2003).
121. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205(4), 825-839 (2008). (Pubitemid 351549881)
122. - T cells in an autoimmune disease model. J. Clin. Invest. 112(7), 1037-1048 (2003).
123. + T suppressor lymphocytes. Clin. Exp. Med. 4(2), 86-92 (2004).
124. + T cells in autoimmune disease. Hum. Immunol. 69(11), 781-789 (2008).
125. + regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13(23), 6947-6958 (2007).
126. + regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med. Oncol. DOI 10.1007/s12032-008-9165- 9 (2009) (Epub ahead of print).
127. Brody JR, Costantino CL, Berger AC et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 8(12), 1930-1934 (2009).
128. Feder-Mengus C, Wyler S, Hudolin T et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur. J. Cancer 44(15), 2266-2275 (2008).
129. Nakamura T, Shima T, Saeki A et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 98(6), 874-881 (2007). (Pubitemid 46691826)
130. Witkiewicz A, Williams TK, Cozzitorto J et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J. Am. Coll. Surg. 206(5), 849-854 (2008).
131. Sharma MD, Baban B, Chandler P et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117(9), 2570-2582 (2007). (Pubitemid 47494358)
132. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9(10), 1269-1274 (2003). (Pubitemid 37279849)
133. Terness P, Bauer TM, Rose L et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196(4), 447-457 (2002). (Pubitemid 34940984)
134. Lee JH, Torisu-Itakara H, Cochran AJ et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11(1), 107-112 (2005).
135. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 56(5), 739-745 (2007). (Pubitemid 46348742)
136. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000). (Pubitemid 30765695)
137. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2(3), 261-268 (2001). (Pubitemid 33706004)
138. Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11(8), 2947-2953 (2005). (Pubitemid 40525197)
139. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006).
140. + T cell expansion in melanoma patients. J. Immunol. 182(9), 5240-5249 (2009).
141. Gao Q, Wang XY, Qiu SJ et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15(3), 971-979 (2009).
142. Jacobs JF, Idema AJ, Bol KF et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro. Oncol. 11(4) 394-402 (2008).
143. Kozako T, Yoshimitsu M, Fujiwara H et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 23(2), 375-382 (2009).
144. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
145. Krambeck AE, Thompson RH, Dong H et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA 103(27), 10391-10396 (2006). (Pubitemid 44051177)
146. Kryczek I, Zou L, Rodriguez P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203(4), 871-881 (2006).
147. Kryczek I, Wei S, Zou L et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J. Immunol. 177(1), 40-44 (2006). (Pubitemid 43939113)
148. Sadun RE, Sachsman SM, Chen X et al. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin. Cancer Res. 13(13), 4016-4025 (2007). (Pubitemid 47037610)
149. Wang L, Fraser CC, Kikly K et al. B7-H3 promotes acute and chronic allograft rejection. Eur. J. Immunol. 35(2), 428-438 (2005). (Pubitemid 40331320)
150. Suh WK, Gajewska BU, Okada H et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4(9), 899-906 (2003). (Pubitemid 37098661)
151. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 24(2), 178-186 (2006).
152. Derre L, Corvaisier M, Charreau B et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J. Immunol. 177(5), 3100-3107 (2006). (Pubitemid 44277827)
153. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv. Immunol. 81, 199-252 (2003). (Pubitemid 38009044)
154. Dunker K, Schlaf G, Bukur J, Altermann WW, Handke D, Seliger B. Expression and regulation of non-classical HLA-G in renal cell carcinoma. Tissue Antigens 72(2), 137-148 (2008). (Pubitemid 352009822)
155. Menendez L, Walker LD, Matyunina LV, Totten KA, Benigno BB, McDonald JF. Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol. Cancer 7, 43 (2008). (Pubitemid 351850956)
156. Lefebvre S, Antoine M, Uzan S et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196(3), 266-274 (2002). (Pubitemid 34189414)
157. Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 14(2), 101-105 (2009).
158. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5(1), 29-41 (2005).
159. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 378(6558), 736-739 (1995).
160. Matarrese P, Tinari A, Mormone E et al. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem. 280(8), 6969-6985 (2005). (Pubitemid 40341253)
161. Chung CD, Patel VP, Moran M, Lewis LA, Miceli MC. Galectin-1 induces partial TCR ζ-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165(7), 3722-3729 (2000). (Pubitemid 32057278)
162. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer 92(2), 305-311 (2005). (Pubitemid 40343146)
163. Andreola G, Rivoltini L, Castelli C et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195(10), 1303-1316 (2002). (Pubitemid 34564332)
164. Valenti R, Huber V, Filipazzi P et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Res. 66(18), 9290-9298 (2006). (Pubitemid 44521151)
165. Coudert JD, Zimmer J, Tomasello E et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106(5), 1711-1717 (2005). (Pubitemid 41208585)
166. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202(5), 583-588 (2005). (Pubitemid 41248410)
167. Oppenheim DE, Roberts SJ, Clarke SL et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6(9), 928-937 (2005).
168. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4(2), 97-105 (2004). (Pubitemid 38198738)
169. Niu G, Bowman T, Huang M et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21(46), 7001-7010 (2002). (Pubitemid 35252974)
170. Kortylewski M, Kujawski M, Wang T et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent anti-tumor immunity. Nat. Med. 11(12), 1314-1321 (2005). (Pubitemid 41752912)
171. Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature 442(7101), 461-465 (2006). (Pubitemid 44264796)
172. Kortylewski M, Xin H, Kujawski M et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15(2), 114-123 (2009).
173. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 63(9), 2150-2157 (2003).
174. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells' ability to break self tolerance and induce anti-tumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116(1), 90-100 (2006). (Pubitemid 43121794)
175. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8(6), 443-454 (2005). (Pubitemid 41773448)
176. Balint K, Xiao M, Pinnix CC et al. Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression. J. Clin. Invest. 115(11), 3166-3176 (2005). (Pubitemid 41567581)
177. Liu ZJ, Xiao M, Balint K et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 66(8), 4182-4190 (2006).
178. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15(3), 195-206 (2009).
179. Lockhart DC, Chan AK, Mak S et al. Loss of T-cell receptor-CD3ζ and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 129(6), 749-756 (2001). (Pubitemid 32493679)
180. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 8(10), 3137-3145 (2002). (Pubitemid 35155023)
181. Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin. Cancer Res. 5(2), 329-334 (1999). (Pubitemid 29085186)
182. Whiteside TL, Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother. 46(4), 175-184 (1998). (Pubitemid 28293817)
183. Biassoni R, Cantoni C, Pende D et al. Human natural killer cell receptors and co-receptors. Immunol. Rev. 181, 203-214 (2001). (Pubitemid 32703408)
184. Pitcher LA, van Oers NS. T-cell receptor signal transmission: who gives an ITAM? Trends Immunol. 24(10), 554-560 (2003).
185. Pignataro L, Pagani D, Brando B, Sambataro G, Scarpati B, Corsi MM. Down-regulation of ζ chain and ζ-associated protein 70 (Zap 70) expression in circulating T lymphocytes in laryngeal squamous cell carcinoma. Anal. Quant. Cytol. Histol. 29(1), 57-62 (2007). (Pubitemid 46333522)
186. Lopez-Santalla M, Krishnan S, Valeri AP et al. Defective CD3ζ chain expression in Herpesvirus saimiri (HVS)-derived T-cell lines in gastric adenocarcinoma. Cell. Immunol. 238(2), 113-122 (2005).
187. Zehbe I, Schmidt M, Maeurer M, Leo C, Hockel M, Pilch H. Different T-cell receptor (TCR) ζ chain expression in cervical cancer and its precursor lesions. Zentralbl. Gynakol. 128(5), 266-270 (2006). (Pubitemid 44545196)
188. Schule JM, Bergkvist L, Hakansson L, Gustafsson B, Hakansson A. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-ζ chain expression. J. Transl. Med. 2(1), 45 (2004). (Pubitemid 40617845)
189. Shondel SM, Helm CW, Gercel-Taylor C, Taylor DD. Differential expression of T-cell CD3-ζ chains in patients with cervical dysplasia before and after treatment. Int. J. Gynecol. Cancer 17(6), 1278-1282 (2007). (Pubitemid 350077347)
190. Ciszak L, Kosmaczewska A, Werynska B, Szteblich A, Jankowska R, Frydecka I. Impaired ζ chain expression and IFN-γ production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol. Rep. 21(1), 173-184 (2009).
191. Mozaffari F, Hansson L, Kiaii S et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br. J. Haematol. 124(3), 315-324 (2004). (Pubitemid 38167981)
192. Frydecka I, Bocko D, Kosmaczewska A, Ciszak L, Morilla R. The effect of peripheral blood lymphocyte stimulation on ζ chain expression and IL-2 production in Hodgkin's disease. Br. J. Cancer 84(10), 1339-1343 (2001). (Pubitemid 32522101)
193. + T cells. J. Exp. Med. 198(4), 569-580 (2003).
194. + T lymphocytes into effector CTL. J. Immunol. 172(11), 6558-6567 (2004).
195. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95(3), 1178-1183 (1998). (Pubitemid 28124932)
196. Horna P, Cuenca A, Cheng F et al. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to anti-tumor immunity. Blood 107(7), 2871-2878 (2006).
197. Cuenca A, Cheng F, Wang H et al. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63(24), 9007-9015 (2003). (Pubitemid 38064082)
198. Drake CG, Doody AD, Mihalyo MA et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7(3), 239-249 (2005).
199. Noonan K, Matsui W, Serafini P et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 65(5), 2026-2034 (2005). (Pubitemid 40478633)
200. Farzad Z, McBride WH, Ogbechi H, Asnong-Holthoff C, Morton DL, Cochran AJ. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma Res. 7(Suppl. 2), S59-S65 (1997). (Pubitemid 27501627)
201. + T-cell immunity against early antigens E2 and E6. Cancer Res. 64(15), 5449-5455 (2004).
202. de Jong A, van der Burg SH, Kwappenberg KM et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 62(2), 472-479 (2002).
203. Nakagawa M, Stites DP, Patel S et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis. 182(2), 595-598 (2000). (Pubitemid 30651059)
204. Palmowski M, Salio M, Dunbar RP, Cerundolo V. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunol. Rev. 188, 155-163 (2002). (Pubitemid 35398873)
205. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5(6), 677-685 (1999). • Demonstrates that while T cells from cancer patients are tolerized against tumor antigens, virus-specific cells from the same patients remain functional. This is an important observation that must be further studied and considered in the design of cancer therapy. (Pubitemid 29289432)
206. + T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251(4998), 1228-1231 (1991).
207. Demotte N, Stroobant V, Courtoy PJ et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 28(3), 414-424 (2008). (Pubitemid 351335307)
208. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 10(11), 3755-3762 (2004). (Pubitemid 38697609)
209. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin. Cancer Res. 15(6), 1931-1939 (2009).
210. Reiss CK, Volenec FJ, Humphrey M, Singla O, Humphrey LJ. The role of the regional lymph node in breast cancer: a comparison between nodal and systemic reactivity. J. Surg. Oncol. 22(4), 249-253 (1983). (Pubitemid 13130114)
211. Laguens G, Coronato S, Laguens R, Portiansky E, Di Girolamo V. Human regional lymph nodes draining cancer exhibit a profound dendritic cell depletion as comparing to those from patients without malignancies. Immunol. Lett. 84(3), 159-162 (2002). (Pubitemid 35292374)
212. Wen DR, Hoon DS, Chang C, Cochran AJ. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol. Immunother. 30(5), 277-282 (1989). (Pubitemid 20002341)
213. Farzad Z, Cochran AJ, McBride WH, Gray D, Wong V, Morton DL. Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res. 50(12), 3585-3588 (1990). (Pubitemid 20194099)
214. Fattorossi A, Battaglia A, Ferrandina G et al. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol. Oncol. 92(1), 106-115 (2004). (Pubitemid 38147379)
215. Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190(10), 1417-1426 (1999).
216. Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol. 160(1), 214-219 (1998). (Pubitemid 29479465)
217. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4(3), 585-593 (1998).
218. Baleeiro RB, Anselmo LB, Soares FA et al. High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-α in lung cancer. Cancer Immunol. Immunother. 57(9), 1335-1345 (2008).
219. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 6(4), R408-415 (2004).
220. Essner R, Kojima M. Surgical and molecular approaches to the sentinel lymph nodes. Ann. Surg. Oncol. 8(9 Suppl.), 31S-34S (2001). (Pubitemid 32947424)
221. Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for anti-tumor CD8 T cell responses. J. Immunol. 181(1), 155-164 (2008).
222. + T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin. Cancer Res. 12(24), 7306-7315 (2006).
223. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316-5326 (2004). (Pubitemid 39100466)
224. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66(6), 3294-3302 (2006).
225. Roszman TL, Brooks WH. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin. Exp. Immunol. 39(2), 395-402 (1980).
226. + T cell immunity is impaired in pancreatic carcinoma patients. J. Immunol. 181(9), 6595-6603 (2008).
227. Radoja S, Rao TD, Hillman D, Frey AB. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J. Immunol. 164(5), 2619-2628 (2000). (Pubitemid 30115493)
228. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118(6), 1991-2001 (2008). • Discusses the potential of chemotherapy to reset the immune response that has been tolerized by the growing tumor in patients, linking current cancer therapy to the immune response.
229. Arteaga CL. Inhibition of TGFβ signaling in cancer therapy. Curr. Opin. Genet. Dev. 16(1), 30-37 (2006).
230. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3(12), 1011-1022 (2004).
231. Castro AG, Neighbors M, Hurst SD et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J. Exp. Med. 192(10), 1529-1534 (2000). (Pubitemid 30953891)
232. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102(3), 964-971 (2003). (Pubitemid 36917791)
233. Soltau J, Drevs J. Mode of action and clinical impact of VEGF signaling inhibitors. Expert Rev. Anticancer Ther. 9(5), 649-662 (2009).
234. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2 Pt 1), 728-734 (2005). (Pubitemid 40116901)
235. Burdelya L, Kujawski M, Niu G et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated anti-tumor effects. J. Immunol. 174(7), 3925-3931 (2005). (Pubitemid 40395966)